WASHINGTON (March 13, 2015) –
Today members of the UN Commission on Narcotic Drugs unanimously rejected the recommendation from the World Health Organization to list 1,4-butanediol (BDO) and gamma-butyrolactone (GBL) as Schedule I substances under the 1971 Convention on Psychotropic Substances. In response to these developments, the American Chemistry Council released the following statement.
“The UN Commission on Narcotic Drugs has unanimously rejected the recommendation from the WHO to list the industrial chemicals GBL and BDO as Schedule I substances under the 1971 Convention on Psychotropic Substances. In fact, the 53 delegates unanimously agreed to not even bring the matter to a formal vote. As the delegates noted, such a classification would have severe economic consequences, disrupt many crucial industries, and affect country development agendas across the global economy.
“We support this decision in recognition of the strong product stewardship initiatives and controls that ACC member companies already have in place for these substances.”
Contact: Bryan Goodman, (202) 997-1606
The CND meets annually when and it considers and adopts a range of decisions and resolutions.
Intersessional meetings of the CND are regularly convened to provide policy guidance to UNODC and owards the end of each year, the CND meets at a reconvened session to consider budgetary and administrative matters as the governing body of the United Nations drug programme.
Subsidiary bodies of the CND are the Subcommission on Illicit Drug Traffic and Related Matters in the Near and Middle East and the meetings of the Heads of National Drug Law Enforcement Agencies (HONLEAs) for Africa, Asia and the Pacific, Latin America and the Carribean, and Europe respectively. The purpose of these meetings is to coordinate activities and to monitor new trends within the respective regions. The recommendations of the subsidiary bodies are submitted to the sessions of the CND for its consideration and follow-up action.